ReviewNutrients2025
Dietary Polyphenols: Luteolin, Quercetin, and Apigenin as Potential Therapeutic Agents in the Treatment of Gliomas.
Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Exploring the Health Effects of Phytoestrogens.Metabolites · 2026Review
- Niemann-Pick C1-Like 1 in Cholesterol Absorption and Homeostasis: Mechanisms, Regulation, and Emerging Phytochemical Inhibitors.Current issues in molecular biology · 2026Review
- Zhigancao decoction alleviates Parkinson's disease via inhibiting TNF/NF-κB and Ras/ERK-mediated neuroinflammation and apoptosis.iScience · 2026Article
- Glioblastoma pathophysiology: roles of aging driven changes in STAT3 interactions with NF-κB dimer components in the modulation of the mitochondrial melatonergic pathway and night-time inflammation resolution.Exploration of targeted anti-tumor therapy · 2026Review
- Human CTR1 Through the Ages: Milestones and Emerging Roles in Disease and Therapy.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyphenols are a group of plant-derived compounds that possess a wide range of possible industrial and pharmaceutical applications. Their mechanisms of action are often enabled by their multifaceted anti-inflammatory and antioxidant properties. As a result of their promising biological profile, they have been the focus of extensive research, which has examined their potential in the treatment of various diseases. These studies have observed that polyphenols may be associated with decreased neoplastic cellular growth, therefore offering valuable potential in oncological therapies. Quercetin, luteolin, and apigenin belong to the group of polyphenols with the most documented efficacy in this regard, particularly against tumors of glial origin. This review gathers information from a multitude of in vitro investigations and animal-model-based research that explore the molecular pathways and biochemical mechanisms engaged by polyphenols which enable their anti-tumoral activity in the central nervous system. Ultimately, this article aims to summarize this research and use this data to comment on the influence of polyphenols on glioma-affected subjects, in addition to exploring methods for increasing their bioavailability for the purposes of clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.